Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bioventus Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Bioventus şirketinin toplam hissedar öz sermayesi $189.1M ve toplam borcu $383.3M olup, bu da borç-öz sermaye oranını 202.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $792.2M ve $603.1M dir. Bioventus 'in FAVÖK'ü $28.4M faiz karşılama oranı 0.7 dur. Şirketin $32.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

202.7%

Borç/özkaynak oranı

US$383.28m

Borç

Faiz karşılama oranı	0.7x
Nakit	US$31.99m
Eşitlik	US$189.06m
Toplam yükümlülükler	US$603.11m
Toplam varlıklar	US$792.17m

Son finansal sağlık güncellemeleri

Recent updates

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Aug 11

Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

Aug 03

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Jun 14

Bioventus: Thoughts After An Active First Year

Mar 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BVS 'nin kısa vadeli varlıkları ( $308.9M ) kısa vadeli yükümlülüklerini ( $231.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: BVS 'un kısa vadeli varlıkları ( $308.9M ) uzun vadeli yükümlülüklerini ( $371.6M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BVS 'nin net borç/öz sermaye oranı ( 185.8% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: BVS şirketinin borç/öz sermaye oranı son 5 yılda 131.3% seviyesinden 202.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan BVS mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: BVS kârlı değildir ancak serbest nakit akışı pozitif olsa ve yılda 52 % oranında azalsa bile 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Bioventus Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Bioventus Inc. announced delayed 10-Q filing

Bioventus Inc. announced delayed 10-Q filing

Recent updates

New minor risk - Profitability

Price target increased by 32% to US$12.33

Forecast breakeven date moved forward to 2024

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Raises Earnings Guidance for the Full Year 2024

Bioventus Inc. to Report Q2, 2024 Results on Aug 06, 2024

Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bioventus Inc. to Report Q1, 2024 Results on May 07, 2024

Bioventus Inc., Annual General Meeting, Jun 11, 2024

Senior VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Provides Earnings Guidance for the Year 2024

New major risk - Revenue and earnings growth

Bioventus Inc. to Report Q4, 2023 Results on Mar 12, 2024

Now 21% undervalued

Bioventus: Bullish On Path To Profitability

Bioventus Inc Announces Executive Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Bioventus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Interim CEO & Director recently bought US$165k worth of stock

Price target increased by 29% to US$4.50

High number of new and inexperienced directors

Bioventus Inc. to Report Q2, 2023 Results on Aug 08, 2023

LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc.

LifeNet Health, Inc. completed the acquisition of Wound Business of Bioventus Inc.

Bioventus Inc. announced delayed 10-Q filing

LifeNet Health, Inc. signed a definitive agreement to acquire Wound Business of Bioventus Inc.

Bioventus Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH).

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Holdings Corporation (NasdaqCM:SWKH).

Kirby Mcinerney LLP Announces the Filing of a Securities Class Action on Behalf Bioventus Inc. Investors

Bioventus Inc. Appoints John A. Bartholdson to the Board as A Class II Director

Bioventus Inc. Announces Impairment of Goodwill for the Three Months Ended October 1, 2022

Bioventus Inc. announced delayed 10-Q filing

Price target decreased to US$9.20

High number of new and inexperienced directors

Price target decreased to US$9.20

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2022

Bioventus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Bioventus: Reiterating Buy Thesis Following Q2 Earnings

Bioventus Inc. Announces Resignation of Stavros G. Vizirgianakis as Member of the Board of Directors

Price target decreased to US$16.40

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioventus Inc. Updates Earnings Guidance for the Full Year 2022

Bioventus Non-GAAP EPS of $0.10 misses by $0.06, revenue of $140.3M beats by $1.97M

Bioventus Receives FDA 510(k) Clearance for SonaStar Elite

Bioventus stock rises as FDA clears SonaStar Elite for use in tumor removal

Bioventus Inc. to Report Q2, 2022 Results on Aug 11, 2022

Bioventus Inc. (NasdaqGS:BVS) completes the acquisition of Cartiheal Ltd for $450 million.

Bioventus Inc. Announces Executive Changes

Bioventus: Strong Value Gap, Insulated Via Leading Market Share

Price target decreased to US$19.40

First quarter 2022 earnings: EPS misses analyst expectations

Bioventus Inc. Reaffirms Earnings Guidance for the Full-Year 2022

Price target increased to US$21.20

High number of new and inexperienced directors

Bioventus Inc. Provides Preliminary Unaudited Earnings Guidance for the First Quarter of 2022

Bioventus Inc. to Report Q1, 2022 Results on May 10, 2022

Bioventus Inc. (NasdaqGS:BVS) acquired unknown remining majority stake in Cartiheal Ltd for approximately $450 million.

Bioventus: Thoughts After An Active First Year

Price target increased to US$21.20

Price target decreased to US$19.50

Full year 2021 earnings: EPS misses analyst expectations

Bioventus Inc. Receives 510(k) Clearance for StimRouter Pain Management Device

Bioventus Inc. Appoints Mark Singleton as Senior Vice President and Principal Accounting Officer, Effective March 21, 2022